What Is XMHQ? Invesco S&P MidCap Quality ETF

Most mid-cap funds hold hundreds of companies at weights so small that no single holding matters. XMHQ does not. TechnipFMC at 3.9%, Illumina at 3.7%, Curtiss-Wright at 3.4%, nVent Electric at 3.3%, Carpenter Technology at 3.2%, Medpace at 2.9%, Exelixis at 2.8% and United Therapeutics at 2.7% are substantial individual positions for a fund in this category.

The reason is the weighting method. Rather than sizing by market capitalisation alone, the index scales weights by quality score, so companies scoring highest receive proportionally more. Concentration is therefore an outcome of the design rather than a side effect, and it means individual company results move this fund in a way they do not move a broad mid-cap index fund.

It also means turnover. Quality scores change as company results change, so the portfolio is reconstituted more actively than a plain market-cap index would be. Weights shift at each rebalance even for companies that stay in the fund, because their scores relative to everyone else's have moved. This is a feature of factor funds generally and one of the costs embedded in owning them, sitting inside results rather than in the stated fee.

Industrials at 30% is the largest sector by a wide margin, followed by technology at 18%, healthcare at 16%, financials at 15% and consumer discretionary at 9%. That is a very different profile from a large-cap quality fund, which would typically be dominated by software and consumer brands.

The named holdings show why. Curtiss-Wright makes engineered components for defence and nuclear applications. nVent Electric makes electrical connection and protection products. Carpenter Technology produces specialty alloys. TechnipFMC provides subsea equipment and services for energy production. These are established industrial businesses with defensible positions in specific niches, which is exactly the profile a quality screen surfaces at this end of the market.

Healthcare arrives through a different route. Illumina in genetic sequencing, Medpace in clinical research services, Exelixis and United Therapeutics in specialty pharmaceuticals are businesses with high margins and, in several cases, entrenched positions. They cluster in the portfolio because the screen rewards profitability.

The 0.25% fee sits above passive mid-cap index funds and below active mid-cap management. That is the standard positioning for a factor product, and the case for paying it depends on whether the quality screen adds something a plain mid-cap fund does not. Nothing on this page speaks to whether it has.

The 0.57% yield is low, which is worth flagging because quality is sometimes conflated with income. It is not. Quality screens select for profitability and balance-sheet strength, and profitable mid-cap companies frequently reinvest heavily rather than distribute. If you want mid-cap income, this fund is not built for it.

XMHQ suits an investor who wants mid-cap exposure filtered toward more profitable, less leveraged businesses and accepts the resulting concentration and turnover. It is the wrong tool as a broad mid-cap core holding, given how concentrated it is, and the wrong tool for someone who wants the cheapest available exposure to the middle of the US market.

Approximate weights as of August 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get XMHQ exposure. Buy shares (or fractional shares) of XMHQ directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so XMHQ sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. XMHQ trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether XMHQ is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks an S&P index of higher-quality US mid-cap companies, screened from the S&P MidCap 400 on measures such as return on equity, accruals and leverage, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is XMHQ a buy?

XMHQ gives you an S&P index of higher-quality US mid-cap companies, screened from the S&P MidCap 400 on measures such as return on equity, accruals and leverage exposure in one ticker at a 0.25% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether XMHQ is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is XMHQ a buy?

XMHQ yields 0.57% as of August 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see XMHQ dividend: yield and schedule.

New to funds like XMHQ? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.